Mediterranean diet in axial spondyloarthritis: an observational study in an Italian monocentric cohort

Francesca Ometto 1, Augusta Ortolan 1†, Davide Farber 1†, Mariagrazia Lorenzin 1, Giulia Dellamaria 2, Giacomo Cozzi 1, Marta Favero 1,3, Romina Valenti 2, Andrea Doria 1 and Roberta Ramonda 1*

Abstract

Background: Little evidence is available about the impact of diet on disease activity of axial spondyloarthritis (axSpA). This study evaluated the impact of a 6-month nutritional advice based on the Mediterranean diet on the disease activity of axSpA.

Methods: We prospectively collected the information of a group of axSpA patients who were offered nutritional advice for a 6-month period, who were compared to axSpA patients followed at the same center who were not on a specific diet. A nutritionist gave suggestions for dietary modification at baseline and thereafter every 2 months until month 6. Adherence to the Mediterranean diet was evaluated with the PREDIMED questionnaire ranging from 0 (no adherence) to 10 (optimal adherence); disease activity was evaluated with ASDAS-CRP. A multivariable regression analysis was conducted to identify independent predictors of PREDIMED and of ASDAS-CRP improvement (improvement ≥ 20% of each score).

Results: A total of 161 patients were included: 81 receiving nutritional advice and 80 controls; 47 in the nutritional group and 63 controls had complete information until month 6. Overall, 40 (36.4%) were females, the mean age was 51.7 ± 1.3 years, and 58 (52.7%) were affected with psoriasis. No relevant change of anthropometric or laboratory measures was observed in either group. Adherence to the Mediterranean diet was moderate (PREDIMED score 6.7 ± 1.8 at baseline; 7.6 ± 2.1 at month 6) and improved more in the nutritional group compared to controls (p = 0.020). Predictors of a PREDIMED improvement ≥ 20% were receiving nutritional advice (OR 4.53, 1.36–15.1, p = 0.014), age (per 10-year increase OR 1.05, 1.02–1.68, p = 0.007), and BMI (OR 0.77, 0.63–0.9, p = 0.006). An ASDAS-CRP improvement ≥ 20% was more frequent in the nutritional group compared to controls (p = 0.020). A PREDIMED improvement ≥ 20% was associated with a ASDAS-CRP improvement ≥ 20% (OR 6.75, 1.8–25.3, p = 0.005). Psoriasis and disease duration were negatively but not significantly associated to the ASDAS-CRP improvement.

Conclusions: Improving adherence to the Mediterranean diet may have a beneficial impact on the activity of axSpA. Patients with a lower BMI and older patients are more prone to modify their diet towards the Mediterranean diet following nutritional advice. Patients with psoriasis may have a limited benefit from dietary improvement.

* Correspondence: roberta.ramonda@unipd.it
Augusta Ortolan and Davide Farber equally contributed to the manuscript.
1Rheumatology Unit, Department of Medicine – DIMED, University of Padova, Via Giustiniani 2, 35128 Padua, Italy
Full list of author information is available at the end of the article

© The Author(s). 2021, corrected publication 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Axial spondyloarthritis (axSpA) is a group of debilitating, chronic, rheumatic diseases characterized by inflammation and new bone formation, mainly involving the spine and the sacroiliac joints. People living with axSpA often turn to lifestyle interventions to complement pharmacological treatment with a particular interest on diet [1]. Among environmental factors, diet has been suggested as a potential modifiable factor to improve inflammation in different rheumatic conditions [2–7]. Mediterranean diet (MD) has shown a protective role in terms of cardiovascular morbidity and overall mortality [6, 8]. MD involves high consumption of olive oil, unrefined carbohydrates, fresh and dried fruit, vegetables, and fish; reduced intake of dairy products and red meat; and moderate red wine consumption; MD is very rich in antioxidants and particularly n-3 polyunsaturated fats, alpha-linoleic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). There is evidence that in rheumatoid arthritis, these nutrients may have a beneficial effect by reducing inflammation, reducing pain and structural damage, and possibly reducing the incidence of the disease [8–13].

There is an unmet need to understand the effects of MD on axSpA, characterized by an increased cardiovascular risk [14–16]. A considerable issue in studies concerning the MD is to assess the adherence to MD. In the PREDIMED trial, a large case-control study on cardiovascular risk, a 14-item questionnaire was introduced with this aim: PREDIMED is consistent with other dietary questionnaires to evaluate MD and is more feasible in clinical practice [17].

We conducted a prospective study in a monocentric cohort of axSpA patients who received a 6-month nutritional advice based on the MD. We evaluated the impact of the nutritional advice on dietary habits, assessed with the PREDIMED questionnaire, and on axSpA disease activity in these patients compared to controls.

Patients and methods
AxSpA patients followed at the Padova University Hospital (Veneto Region, Italy) were offered advice by a nutritionist for a 6-month period, starting in May 2019. We collected the information of the patients in the nutritional group (N) and of a comparable group of consecutive axSpA patients who did not receive nutritional advice, controls (C). All patients were assessed every 6 months (T0 and T6) by a rheumatologist trained in the clinical assessment of axSpA and blinded to the study group. Patients in N underwent the nutritional evaluation in the day of the visits (T0 and T6) and in between every 2 months. Clinical assessment, laboratory tests, and assessment of the adherence to the MD and of cardiovascular risk were collected for all patients at T0 and T6.

Patients
We included patients who underwent two consecutive rheumatological assessments since May 2019. Only patients fulfilling the following criteria were included in the analysis: age ≥ 18 years, diagnosis of axial involvement (axSpA) according to ASAS 2009 criteria [18], and stable (≥ 6 months) biological/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) treatment. Exclusion criteria were rheumatological conditions other than axSpA, ongoing specific diet or optimal MD, and concomitant diabetes mellitus/metabolic syndrome. Patients were allowed to change treatment in case of suboptimal disease control. However, in order to ensure a homogenous cohort of patients with stable treatment, patients with very high disease activity (i.e., ASDAS-CRP ≥ 3.5) were excluded. Eighty-one patients in N and 80 controls were consecutively enrolled.

The local medical ethical committee approved the study (Protocol No. 52723), and informed consent was obtained from all patients at study inclusion. The study was conducted in compliance with the Declaration of Helsinki of 1975/1983.

Nutritional advice
Patients in N underwent an interview with a nutritionist at T0. Dietary habits were assessed through the PREDIMED questionnaire [17] and through a 24-h recall of meals consumed the previous day. Based on these evaluations, the nutritionist suggested dietary modifications in order to improve their adherence to the MD. Key recommendations of the nutritionist were as follows: fractionate daily caloric intake into 3 main meals and two snacks; ensure a daily caloric intake mainly consisting of carbohydrates (55%) preferably with low glycemic index, followed by fats (20–30%) and proteins (10–15%); include adequate amounts of fibers (25–30 g daily) and water (1.5–2 l daily); consumption of vegetables, fruits, sugar-free cereals, and olive oil in every meal; use of olive oil as the main culinary fat; daily consumption of low-fat dairy products and nuts and a moderate wine...
consumption; weekly consumption of fish, white meat, and legumes; reduced weekly consumption of red meat, eggs, and potatoes; limit the use of salt; and only occasional consume of pastries, sweets, and soft drinks. Importantly, adoption of a non-sedentary lifestyle and regular physical activity were also recommended (Additional file 1) [18]. Every 2 months, the nutritionist asked the patients about their dietary habits and recalled the dietary modifications suggested at T0.

Clinical assessment
At T0, sociodemographic information and information about disease history and treatments were collected. Clinical assessments were collected at T0 and T6 and included weight, height, body mass index (BMI), blood pressure, tender joint count (TJC), swollen joint count (SJ), dactylitis, Bath Ankylosing Spondylitis Score Metrology Index (BASMI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), Leeds Enthesitis Index (LEI), Psoriasis Area Severity Index (PASI), physician assessment of disease on visual analog scale (VAS), and patient-reported outcomes (PREDIMED questionnaire, the Italian version of 5-item compliance questionnaire for rheumatology (I-CQR5)) [19], Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Health Assessment Questionnaire (HAQ), patient VAS global, and patient VAS pain). Ankylosing Spondylitis Disease Activity Score (ASDAS) with C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) scores were also computed. The following laboratory measures were collected at T0 and T6 for disease activity assessment, diet, and cardiovascular risk monitoring in clinical practice [16]: hemoglobin (HB), white blood count (WBC), platelets, (PLT) ESR, CRP, urate, glycated hemoglobin (HbA1c), fasting blood glucose (FBG), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HLD-c), triglycerides, total cholesterol (TC), glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), gamma-glutamyltransferase (GGT), creatinine, and thyroid-stimulating hormone (TSH).

Dietary and lifestyle assessments
In both groups, patients were administered the Italian version of the PREDIMED questionnaire (Additional file 2) at T0 and T6. The score is computed as the sum of scores of each question, with higher values indicating a higher adherence to the MD (≤ 5 low adherence, 6–9 moderate adherence, ≥ 10 high adherence). Questions about continuous physical activity (yes/no) and the frequency of physical activity (< 1/weekly; 1/weekly; ≥ 2 weekly) were also administered.

Cardiovascular risk assessment
Cardiovascular risk assessment in this study was evaluated with the systematic coronary risk evaluation (SCORE) and CUORE indices at T0 and T6. In chronic inflammatory arthritis, SCORE for the appropriate country (i.e., low-risk countries for Italy) is recommended [20]; alternatively, the cardiovascular risk index recommended by national guidelines may be used, such as the Italian CUORE [21]. The computation of each index is detailed in Additional file 3.

Treatments
b/tsDMARDs considered were adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab, ustekinumab, and apremilast; csDMARD were sulfasalazine and methotrexate. NSAIDs and low-dose corticosteroid treatment were also admitted.

Study outcomes
To evaluate an improvement in the adherence to the MD, the T0–T6 change in the PREDIMED score was considered. An improvement ≥ 20% of the T0 value was considered as a positive outcome. As a measure of clinical improvement, the ASDAS-CRP index was considered, which comprehends both clinical and laboratory measures [22]. The CRP-based index was also chosen, since it is required for the medical prescription of rheumatological treatments in the Veneto Region. The T0–T6 change was computed and an improvement ≥ 20% of the T0 value was considered as a positive outcome. Despite measures for clinically relevant improvement with ASDAS-CRP are available [23], a 20% cutoff was deemed appropriate in order to include also small improvements in clinical activity after a 6-month dietary modification.

Statistical analysis
Characteristics of the patients are presented in all the study population and according to the study group. To identify potential biases in the study, univariate analysis tests were run to identify potential differences in T0 characteristics between C and N. Multivariate analysis was run to identify determinants of a ≥ 20% improvement from T0 in the PREDIMED score and in ASDAS-CRP. Variables included in the multivariate analysis were all those achieving a p < 0.10 in univariate analysis. Collinearity was assessed by the variance inflation factor (VIF), adopting a cutoff of VIF = 2 as an exclusion criterion. A logistic regression model was used, with a backward elimination approach. The results of multivariate logistic regression analysis are presented as the odds ratio (OR) with the corresponding 95% confidence interval (CI). Analyses were performed using SPSS version 24.0.
Results
Among a total of 378 axSpA evaluated patients, 222 fulfilled the inclusion criteria and were willing to participate in the study; 61 were excluded because of an ongoing specific diet, other rheumatological overlapping conditions, diabetes mellitus/metabolic syndrome, or very high disease activity. One hundred and sixty-one patients were included in the study: 81 in N and 80 in C. Of these patients, 47 in N and 63 in C completed the evaluation at T6. T6 evaluations of patients included in the study were completed in April 2020.

Characteristics of the patients
Characteristics of all patients and patients in N and C are reported in Table 1. Among 110 patients with complete data, 40 (36.4%) were females and 70 males (63.6%): the mean age was 51.7 ± 1.3 years, 58 (52.7%) patients were affected with psoriasis, and mean disease duration was 15.3 ± 9.7 years. No significant difference emerged between subjects in the two study groups at T0.

Clinical measures
Clinical and laboratory characteristics of the patients at T0 and T6 and the T0–T6 change are reported in Tables 2 and 3. No significant differences emerged between the two groups in characteristics at T0 and T6. A significant difference was observed in the ASDAS-CRP T0–T6 change which improved more in N (Δ = −0.1 ± 0.7) compared to C (Δ 0.2 ± 0.8) (p = 0.003). A significant, but slight, worsening of the HbA1c levels was also observed in N (Δ 7.3 ± 21.5) compared to C (Δ 2.7 ± 5.6) (p = 0.01).

Notably, a significant difference was observed in the regular physical activity reported by patients at T6 which was more frequent in N vs. C (p < 0.01) (Table 2).

The PREDIMED questionnaire
The results of the PREDIMED questionnaire at T0 and T6 and the T0–T6 change are reported in Table 4 and in Fig. 1. Overall, adherence to MD was moderate: PREDIMED score was 6.7 ± 1.8 at T0 and 7.6 ± 2.1 at T6. No significant difference in T0 values was observed in the total PREDIMED score between N (7 ± 2.1) and C (6.6 ± 1.6), while a significant difference was observed at T6 between N (8.6 ± 1.9) and C (6.8 ± 2) (p < 0.01) and in the T0–T6 change in N (Δ 1.6 ± 2.4) compared to C (Δ 0.4 ± 2) (p = 0.020). A ≥ 20% improvement in the PREDIMED from T0 was significantly more frequent in N (22/47, 46.8%) compared to C (13/63, 20.6%) (p < 0.01) (Fig. 1).

A significant difference was found at T0 in the frequency of positive response of question 12 (mixed nuts per week) which was higher in N. At T6, a significant difference was found in the frequency of positive responses between the two study groups in the following questions: 4 (fruit per day), 10 (fish consumption per week), and 13 (white meat over red meat consumption), which were higher in N. Furthermore, we observed more frequently an improvement in N compared to C in question 1 (olive oil as the main culinary fat), 4 (fruit per day), 12 (mixed nuts per week), and almost significant in question 2 (olive oil consumption per day) (Table 4 and Additional file 4).

Predictors of PREDIMED improvement
Characteristics of the patients and of clinical and laboratory values at T0 are reported in Additional file 5 according to the achievement of a ≥ 20% improvement in the PREDIMED score at T6. In the multivariable analysis, the following variables were included: receiving nutritional advice (group N), age, full- or part-time employment, psoriasis, disease duration, use of TNF inhibitors, concomitant treatments, BMI, patient VAS global, and CRP. No variable was excluded because of collinearity. N was associated with a higher probability of achieving an improvement of the PREDIMED score compared to C (OR 4.53, 1.36–15.1, p = 0.014), together with older age (per 10-year increase OR 1.05, 1.02–1.68, p = 0.007) (Fig. 2). BMI was associated with a lower probability of achieving an improvement of the PREDIMED score: per unit increase OR 0.77, 0.63–0.9, p = 0.006.

Predictors of ASDAS-CRP improvement
Characteristics of the patients and of clinical and laboratory values at T0 are reported in Additional file 6 according to the achievement of a ≥ 20% improvement in the ASDAS-CRP score at T6. A ≥ 20% improvement in the ASDAS-CRP at T6 was significantly more frequent in N (8/47, 17%) compared to C (6/63, 9.5%) (p = 0.020) and especially in those who achieved a ≥ 20% PREDIMED improvement compared to those who did not: 12/35 (34.3%) and 2/75 (2.7%); p < 0.001 (Fig. 1).

In the multivariable analysis of predictors of a ≥ 20% improvement in ASDAS-CRP, the following variables were included: receiving nutritional advice (group N), ≥ 20% improvement in PREDIMED score, age, psoriasis, use of steroids, concomitant treatments, disease duration, and patient VAS global and patient VAS pain. Steroid use was excluded because of collinearity with psoriasis (VIF = 2.71). A ≥ 20% improvement in the PREDIMED score resulted in being associated with a 6-fold increased probability of achieving the ASDAS-CRP improvement (OR 6.75, 1.8–25.3, p = 0.005). Psoriasis and a longer disease duration resulted in being negatively associated with ASDAS-CRP improvement, although non-significantly (Fig. 2).
Overall, a low cardiovascular risk was observed in all patients in our study. At T0, SCORE was 1.7 ± 1.7 in all patients and most patients were in the lowest risk class according to CUORE (specifically 42/117, 53.7%) (Additional file 7). No significant change from T0 and in C and N were observed in SCORE or CUORE, although a trend toward a more consistent improvement of SCORE was observed in N compared to C: −0.4 ± 0.7 in N vs −0.1 ± 1 in C ($p = 0.131$). No significant difference was observed in the modification of SCORE and CUORE at T6 in the patients who improved for ≥20% in the PRE-DIMED score from T0.

**Discussion**
This is the first study that evaluated the impact of a 6-month nutritional advice based on the MD in patients affected with axSpA. Nutritional advice was effective in improving the adherence to the MD in almost half of the patients. Older patients and those with a lower BMI

### Table 1 Characteristics of the patients

|                                   | All patients* | N   | C   |
|-----------------------------------|---------------|-----|-----|
| Number of patients                | 110           | 47  | 63  |
| Females, n (%)                    | 40 (36.4)     | 18 (38.3) | 22 (34.9) |
| Age, years, mean ± SD             | 51.7 ± 1.3    | 53.0 ± 1.3 | 49.6 ± 1.3 |
| Schooling                         |               |     |     |
| Primary school, n (%)             | 8 (7.3)       | 4 (8.5) | 4 (6.3) |
| Middle school, n (%)              | 45 (40.9)     | 18 (38.3) | 27 (42.9) |
| Secondary school, n (%)           | 36 (32.7)     | 17 (36.2) | 19 (30.2) |
| University, n (%)                 | 21 (19.1)     | 8 (17) | 13 (20.6) |
| Social status                     |               |     |     |
| Living with parents and family, n (%) | 15 (13.6) | 6 (12.8) | 9 (14.3) |
| Living alone, n (%)               | 16 (14.5)     | 7 (14.9) | 9 (14.3) |
| Living with partner and family, n (%) | 71 (64.5) | 29 (61.7) | 42 (66.7) |
| Others, n (%)                     | 8 (7.3)       | 5 (10.6) | 3 (4.8) |
| Full- or part-time employed, n (%) | 76 (69.1) | 29 (61.7) | 47 (74.6) |
| Smoking, current, n (%)           | 17 (15.5)     | 5 (10.6) | 12 (19) |
| HLA-B27 positivity, n (%)         | 58 (52.7)     | 22 (46.8) | 36 (57.1) |
| Psoriasis, n (%)                  | 58 (50.7)     | 26 (55.3) | 32 (50.8) |
| Uveitis, n (%)                    | 7 (6.4)       | 5 (10.6) | 2 (3.2) |
| Disease duration (years), mean ± SD | 15.3 ± 9.7  | 15.7 ± 10 | 15 ± 9.5 |
| Mechanism of action of current b/tsDMARD |   |     |     |
| TNF inhibitors, n (%)             | 85 (77.3)     | 40 (85.1) | 45 (71.4) |
| IL-12/23 inhibitors, n (%)        | 9 (8.2)       | 1 (2.1) | 8 (12.7) |
| IL-17 Inhibitors, n (%)           | 14 (12.7)     | 6 (12.8) | 8 (12.7) |
| PDE4 inhibitors, n (%)            | 2 (1.8)       | 0 (0) | 2 (3.2) |
| Duration of b/tsDMARD treatment overall, years, mean ± SD | 5 ± 4.1 | 5.8 ± 4.5 | 4.5 ± 3.8 |
| Low-dose b/tsDMARD treatment, n (%) | 28 (25.5) | 11 (23.4) | 17 (27) |
| b/tsDMARD naïve patients, n (%)   | 81 (73.6)     | 37 (78.7) | 44 (69.8) |
| No. of b/tsDMARD treatments, mean ± SD | 1.5 ± 0.9  | 1.3 ± 0.7 | 1.6 ± 1.1 |
| Steroid, n (%)                    | 9 (8.2)       | 1 (2.1) | 8 (12.7) |
| NSAID, n (%)                      | 76 (69.1)     | 30 (63.8) | 46 (73) |
| csDMARD, n (%)                    | 14 (12.7)     | 5 (10.6) | 9 (14.3) |
| Concomitant treatments, n (%)     | 62 (56.4)     | 27 (57.4) | 35 (55.6) |
| Distance from clinic, km, mean ± SD | 36.1 ± 47.2 | 31.1 ± 34.2 | 39.7 ± 54.9 |

*No significant differences were observed among any of the variables between the two groups at T0

N nutritional group, C control group, b/tsDMARD biological/targeted synthetic disease-modifying antirheumatic drug, NSAID non-steroidal anti-inflammatory drug, csDMARD conventional synthetic disease-modifying antirheumatic drug

**Cardiovascular risk assessment**
Overall, a low cardiovascular risk was observed in all patients in our study. At T0, SCORE was 1.7 ± 1.7 in all patients and most patients were in the lowest risk class according to CUORE (specifically 42/117, 53.7%) (Additional file 7). No significant change from T0 and in C and N were observed in SCORE or CUORE, although a trend toward a more consistent improvement of SCORE was observed in N compared to C: −0.4 ± 0.7 in N vs −0.1 ± 1 in C ($p = 0.131$). No significant difference was observed in the modification of SCORE and CUORE at T6 in the patients who improved for ≥20% in the PRE-DIMED score from T0.
Table 2 Clinical measures

|                  | T0 All patients | N | C | T6 All patients | N | C | Δ T0–T6 All patients | N | C |
|------------------|----------------|---|---|----------------|---|---|----------------------|---|---|
| Number of patients | 110            | 47 | 63 | 110            | 47 | 63 |                      | 110 | 47 | 63 |
| Weight, kg, mean ± SD | 78.1 ± 16.6 | 75.9 ± 15 | 79.8 ± 17.6 | 77.9 ± 16.3 | 75.2 ± 14.2 | 79.8 ± 17.5 | -0.3 ± 2.9 | -0.7 ± 3 | 0 ± 2.8 |
| Height, cm, mean ± SD | 170 ± 10 | 168 ± 8 | 171 ± 10 | -   | -   | -   |                      | -   | -   | -   |
| BMI, kg/meters², mean ± SD | 26.5 ± 5.4 | 26.5 ± 4.3 | 26.6 ± 6.1 | 26.4 ± 5.3 | 26.3 ± 4 | 26.6 ± 6.1 | -0.1 ± 0.9 | -0.2 ± 0.9 | 0 ± 0.9 |
| SBP, mmHg, mean ± SD | 128.7 ± 14.9 | 128.7 ± 15 | 128.7 ± 15 | 128.9 ± 13.3 | 128.9 ± 13.6 | 128.9 ± 13.2 | 0.2 ± 1.1 | 0.2 ± 1 | 0.2 ± 1.2 |
| DBP, mmHg, mean ± SD | 81.1 ± 8.7 | 80.5 ± 8.2 | 81.5 ± 9.1 | 82.8 ± 9 | 81.5 ± 8.2 | 83.8 ± 9.6 | 1.7 ± 5.9 | 1 ± 4.8 | 2.3 ± 6.7 |
| ASDAS-CRP, mean ± SD* | 2.1 ± 1 | 2.1 ± 0.9 | 2.1 ± 1 | 2 ± 1.1 | 1.8 ± 0.9 | 2.1 ± 1.2 | 0.1 ± 0.8 | -0.1 ± 0.7 | 0.2 ± 0.8 |
| ASDAS-ESR, mean ± SD | 2.2 ± 1 | 2.2 ± 1 | 2.2 ± 1 | 2.1 ± 1.1 | 1.9 ± 1 | 2.2 ± 1.2 | 0.1 ± 0.8 | -0.2 ± 0.7 | 0.2 ± 0.8 |
| BASDAI, mean ± SD | 37.6 ± 23 | 37.4 ± 23.2 | 37.7 ± 22.9 | 39.3 ± 24.1 | 37.3 ± 23.6 | 41.2 ± 24.6 | 0.2 ± 1.8 | -0.1 ± 1.9 | 0.4 ± 1.6 |
| BASFI, mean ± SD | 20.5 ± 21.4 | 21.6 ± 19.2 | 19.7 ± 23 | 19.8 ± 19.6 | 19.1 ± 18.8 | 20.5 ± 20.4 | -0.1 ± 1.8 | -0.3 ± 1.5 | 0.1 ± 2.6 |
| BASMI, mean ± SD | 1.6 ± 2 | 1.9 ± 2.2 | 1.4 ± 1.7 | 1.8 ± 2.1 | 1.9 ± 2.4 | 1.7 ± 1.9 | 0.2 ± 0.8 | 0.2 ± 0.6 | 0.3 ± 1 |
| Patient VAS global, mean ± SD | 35.5 ± 31.5 | 36.5 ± 30.8 | 34.8 ± 32.3 | 36.5 ± 29.6 | 34.9 ± 30 | 37.6 ± 29.6 | 1.9 ± 31.6 | 0.3 ± 31.8 | 3.1 ± 31.6 |
| Patient VAS pain, mean ± SD | 35.3 ± 29.5 | 35.5 ± 29.3 | 35.1 ± 29.9 | 38.4 ± 30.5 | 33.9 ± 30 | 37.5 ± 30.4 | 3.2 ± 27.9 | -0.4 ± 26.8 | 3.7 ± 28.5 |
| Physician VAS, mean ± SD | 35.8 ± 28 | 34.7 ± 29.3 | 36.7 ± 29.9 | 32.3 ± 25.2 | 29.7 ± 26.2 | 34.3 ± 24.4 | -3.5 ± 17.5 | -5 ± 17.4 | -2.4 ± 17.7 |
| HAQ, mean ± SD | 0.5 ± 0.5 | 0.5 ± 0.5 | 0.5 ± 0.6 | 0.4 ± 0.5 | 0.4 ± 0.4 | 0.5 ± 0.5 | 0 ± 0.3 | 0 ± 0.4 | 0 ± 0.3 |
| TJC, mean ± SD | 1.1 ± 2.3 | 0.8 ± 2.1 | 1.4 ± 2.5 | 0.9 ± 2 | 0.8 ± 2 | 0.9 ± 1.9 | -0.3 ± 1.8 | 0 ± 1.6 | -0.4 ± 2 |
| SJC, mean ± SD | 0.3 ± 1.3 | 0.4 ± 2 | 0.1 ± 0.5 | 0.2 ± 1.3 | 0.3 ± 1.8 | 0.2 ± 0.8 | 0 ± 1.8 | -0.1 ± 2.7 | 0 ± 0.7 |
| Dactylitis, n (%) | 5 (4.5) | 2 (4.3) | 3 (4.8) | 2 (1.8) | 0 (0) | 2 (3.2) | 2 (1.8) | 0 (0) | 2 (3.2) |
| MASES, mean ± SD | 1 ± 2.2 | 1.6 ± 3 | 0.5 ± 1.3 | 1.1 ± 2 | 1.3 ± 2.2 | 1 ± 1.8 | 0.2 ± 1.6 | -0.3 ± 1.4 | 0.5 ± 1.6 |
| LEI, mean ± SD | 0.2 ± 0.8 | 0.3 ± 1 | 0.2 ± 0.6 | 0.3 ± 1 | 0.5 ± 1.3 | 0.2 ± 0.6 | 0.1 ± 0.9 | 0.1 ± 1 | 0.1 ± 0.6 |
| PASI, mean ± SD | 0.9 ± 1.9 | 1 ± 2.7 | 0.7 ± 1.2 | 0.8 ± 2.1 | 1.1 ± 3 | 0.7 ± 1.4 | -0.1 ± 1 | 0 ± 0.6 | -0.1 ± 1.3 |
| I-CQRS poorly adherent, n (%)* | 9 (8.2) | 3 (6.4) | 6 (9.5) | - | - | - | - | - | - |
| Regular physical activity, n (%) | 47 (42.7) | 21 (44.7) | 26 (41.3) | 58 (52.7) | 29 (41.5) | 29 (46.2) | 11 (10.0) | 8 (17) | 3 (4.8) |

No significant difference was observed among any of the variables between the two groups at T0 and at T6, except for regular physical activity at T6 (p < 0.01).

N nutritional group, C control group, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score with C-reactive protein, ASDAS-ESR Ankylosing Spondylitis Disease Activity Score with erythrocyte sedimentation rate, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Score Metrology Index, VAS visual analogue scale, HAQ Health Assessment Questionnaire, TJC tender joint count, SJC swollen joint count, MASES Maastricht Ankylosing Spondylitis Enthesitis Score, LEI Leeds Enthesitis Index, PASI Psoriasis Area Severity Index, I-CQRS Italian version of 5-item Compliance Questionnaire for Rheumatology.

*A significant change in ASDAS-CRP and regular physical activity was observed in the change of the two timepoints in the N compared to C (p = 0.003 and p < 0.01, respectively)

were more prone to modify their diet after nutritional advice. Furthermore, patients who achieved an increase in the PREDIMED score seemed to benefit from an improvement in the disease activity of axSpA, although this may be more difficult in patients affected by psoriasis. Despite the brief study period, during which no major changes in laboratory or anthropometric measures were observed, a numerical improvement in the indices of cardiovascular risk was noted, particularly in patients receiving nutritional advice.

About one-third of the patients initially enrolled in the study dropped out and could not complete the evaluation at month 6. The main reason for lost-to-follow-up was the isolation protocol during the COVID-19 emergency in Italy in February–April 2020.

An overall moderate adherence to the MD emerged at baseline in the entire cohort with most of the patients reporting a moderate adherence to MD. This finding is consistent with a study conducted in another Italian cohort of psoriatic arthritis patients showing very similar
### Table 3: Laboratory Measures

|                  | T0          |        |        | T6          |        |        | ΔT0–T6   |        |        |
|------------------|-------------|--------|--------|-------------|--------|--------|----------|--------|--------|
|                  | All patients| N      | C      | All patients| N      | C      | All patients| N      | C      |
| Hb, g/dl, mean ± SD | 14.3 ± 1.3 | 14.3 ± 1.1 | 14.2 ± 1.4 | 14.4 ± 1.2 | 14.4 ± 1.1 | 14.4 ± 1.3 | 0.1 ± 0.9 | 0.1 ± 1 | 0.1 ± 0.8 |
| WBC, 1/mm³, mean ± SD | 6684.6 ± 1809.9 | 6681.9 ± 1722.3 | 6731.4 ± 1885 | 6911.2 ± 1750.7 | 6649.6 ± 1512.8 | 7106.3 ± 1897.3 | 226.5 ± 1505.4 | 227.7 ± 1347.8 | 374.9 ± 1607.5 |
| PLT, 10³/mm³, mean ± SD | 267.5 ± 229.1 | 241.5 ± 59.2 | 287 ± 298 | 247.5 ± 65.2 | 239.2 ± 60.5 | 253.6 ± 68.2 | −20.1 ± 225.5 | −12.3 ± 34.4 | −33.4 ± 296.8 |
| CRP, mg/L, mean ± SD | 3.4 ± 6.2 | 3.2 ± 3.9 | 3.7 ± 7.4 | 3.5 ± 5.6 | 2.6 ± 3.1 | 4.1 ± 6.9 | 0.1 ± 6.4 | −0.1 ± 4 | 0.3 ± 7.7 |
| ESR, mm/h, mean ± SD | 15.2 ± 17.1 | 13.8 ± 14.4 | 16.3 ± 18.9 | 14.1 ± 13.6 | 11.6 ± 10.3 | 16 ± 15.5 | −1.1 ± 13.1 | −2.2 ± 9.7 | −0.3 ± 15.2 |
| Urate, mg/dl, mean ± SD | 5.5 ± 1.1 | 5.4 ± 1 | 5.6 ± 1.3 | 4.8 ± 1.8 | 4.7 ± 2 | 4.9 ± 1.7 | −0.5 ± 1.6 | −0.1 ± 0.3 | −0.7 ± 1.9 |
| HbA1c, mmol/mol, mean ± SD** | 47.4 ± 15 | 52.5 ± 21.1 | 44 ± 9 | 59.6 ± 20.7 | 63.2 ± 26.1 | 57.7 ± 18.5 | 4.5 ± 13.3 | 7.3 ± 21.5 | 2.7 ± 5.6 |
| FBG, mg/dl, mean ± SD* | 105.1 ± 26.5 | 1133.3 ± 30.4 | 100.9 ± 23.8 | 101.6 ± 27.2 | 98.9 ± 25 | 103.5 ± 28.9 | 2.4 ± 21.4 | −7.4 ± 14.7 | 7.3 ± 22.9 |
| LDL-c, mg/dl, mean ± SD** | 130.8 ± 36.5 | 132.3 ± 35 | 129.7 ± 38.4 | 130.6 ± 34.7 | 125.7 ± 34.8 | 134.4 ± 34.5 | −1.2 ± 24.1 | −5.2 ± 31.6 | 1.8 ± 16.7 |
| HDL-c, mg/dl, mean ± SD** | 54.7 ± 15.4 | 61.1 ± 17.5 | 49.8 ± 11.7 | 55.7 ± 17.5 | 59.2 ± 21.2 | 53 ± 13.6 | 0 ± 8 | −1.1 ± 7.3 | 0.9 ± 8.5 |
| TC, mg/dl, mean ± SD | 209.7 ± 45.1 | 211.4 ± 41.2 | 208.5 ± 48.4 | 205.6 ± 37.2 | 204.9 ± 40.6 | 206.2 ± 34.6 | 2.1 ± 26 | −0.1 ± 29.5 | 3.8 ± 23.3 |
| Triglycerides, mg/dl, mean ± SD | 123.2 ± 63.4 | 118.8 ± 57.3 | 127.4 ± 65.7 | 125.3 ± 57.8 | 115.5 ± 52.5 | 130.8 ± 60.6 | 2.5 ± 44 | −3.3 ± 51.1 | 3.8 ± 38.1 |
| TC/HDL-c ratio, mean ± SD | 4 ± 1.4 | 3.8 ± 1.3 | 4.2 ± 1.4 | 4.1 ± 1.4 | 3.9 ± 1.3 | 4.3 ± 1.5 | 0.1 ± 0.5 | 0 ± 0.6 | 0.1 ± 0.4 |
| GOT, U/L, mean ± SD | 22.4 ± 8.7 | 23.1 ± 9.1 | 21.8 ± 8.5 | 23.1 ± 8.2 | 23.5 ± 8.6 | 22.9 ± 8 | 0.8 ± 8 | 0.4 ± 7.9 | 1 ± 8.2 |
| GPT, U/L, mean ± SD | 24.4 ± 15 | 24.7 ± 15.2 | 24.3 ± 15 | 25.1 ± 13.6 | 25.1 ± 12.6 | 25.1 ± 14.4 | 0.7 ± 13.1 | 0.4 ± 11.3 | 0.9 ± 14.3 |
| GGT, U/L, mean ± SD | 21.8 ± 19.1 | 23.7 ± 20.3 | 20.5 ± 18.1 | 23.5 ± 19.7 | 24.6 ± 23.4 | 22.7 ± 16.5 | 1.7 ± 20.2 | 1 ± 16.6 | 2.2 ± 22.5 |
| Creatinine, mg/dl, mean ± SD | 0.9 ± 0.2 | 0.9 ± 0.3 | 0.9 ± 0.2 | 1 ± 1.4 | 1.2 ± 2.1 | 0.8 ± 0.2 | 0.1 ± 1.3 | 0.3 ± 2 | 0 ± 0.1 |
| TSH, μU/ml, mean ± SD | 3.2 ± 2 | 2.9 ± 0.5 | 3.3 ± 2 | 3.5 ± 2.6 | 3.6 ± 3.6 | 3.4 ± 1.9 | 0.3w ± 3.7 | 0.5 ± 6.4 | 0.2 ± 0.4 |

* N nutritional group, C control group, HB hemoglobin, WBC white blood count, PLT platelets, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HbA1c glycosylated hemoglobin, FBG fasting blood glucose, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol, TC total cholesterol, GOT glutamic oxaloacetic transaminase, GPT glutamic pyruvic transaminase, GGT gamma-glutamyltransferase, TSH thyroid-stimulating hormone

** A significant difference in the HDL-c levels was observed at T0 comparing the N and C (p = 0.039)

*** A significant difference in HbA1c was observed at T6 in the N compared to C (p = 0.048)

The multivariable analysis revealed that receiving nutritional advice increased by almost 5-fold the odds of achieving a ≥20% improvement in adherence to MD. The patients in the nutritional group have therefore undoubtedly benefitted from the suggestions provided by the nutritionist. Also, tight follow-up with frequent assessments may have improved the adherence to the given dietary recommendations. Patients with a lower BMI were more prone to achieve a PREDIMED improvement, which may reflect the fact that patients with an already good dietary control are more acquainted with food management and with the specific nutritional properties of the food. In addition, we observed that older patients (i.e., in their fifties) were more prone to improve their diet. This may be due to various factors: older patients may have more time to prepare meals.
A slight worsening of HbA1c was observed in the patients who initiated the MD nutritional intervention compared to other diets which recommended low sugar intake (including non-sugary cereals) and complex carbohydrates with low glycemic index may be beneficial. Another possible explanation is that patients may have consumed predominantly fruits with a high glycemic index.

Adherence to MD emerged as the most significant predictor of improved disease activity in our study (≥ 20% vs. baseline, PREDIMED), resulting in a 7-fold increased likelihood of improving ASDAS-CRP as well.

Previous studies on MD nutritional interventions in rheumatic diseases have shown a beneficial effect on disease control and possibly a reduced incidence of inflammatory arthritis [2, 4, 5, 8, 9, 11, 13, 18, 22, 23, 25], though no comparable studies are currently available in axSpA patients. A recent Italian cross-sectional study, limited to psoriatic arthritis patients, confirmed the association between a better adherence to MD and improved clinical activity indices [24]. Two studies conducted in England and in Sweden showed that the implementation of MD in patients with rheumatoid arthritis was mainly associated with an improved perception of pain and disease activity but also clinical indices (e.g., CRP) [26, 27]. Likewise, in our study, both the patient’s evaluation (on a VAS scale) and the laboratory measures of inflammation (i.e., CRP) improved in the patients who initiated MD.

| Table 4 Adherence to the Mediterranean diet assessed with the PREDIMED questionnaire |
|---------------------------------------------------------------|-------------------|-------------------|-------------------|
| **T0** All patients | N | C | **T6** All patients | N | C | **T0–T6 change** All patients | N | C |
|---------------------------------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Total score, mean ± SD* | 6.7 ± 1.8 | 7 ± 2.1 | 6.6 ± 1.6 | 7.6 ± 2.1 | 8.6 ± 1.9 | 6.8 ± 2 | 1 ± 2.3 | 1.6 ± 2.4 | 0.4 ± 2 |
| Lowest adherence, n (%) | 25 (22.7) | 10 (21.3) | 15 (23.8) | 16 (14) | 2 (4.3) | 14 (22.6) | – | – | – |
| Moderate adherence, n (%) | 85 (77.3) | 37 (78.7) | 48 (76.2) | 71 (64) | 28 (59.6) | 43 (67.9) | – | – | – |
| Highest adherence, n (%) | 0 (0) | 0 (0) | 0 (0) | 23 (22) | 17 (36.2) | 6 (9.4) | – | – | – |
| Question 1, n (%) | 87 (79.1) | 37 (78.7) | 50 (79.4) | 90 (82) | 42 (89.4) | 48 (75.5) | 8 (7) | 7 (12.8) | 1 (1.9) |
| Question 2, n (%) | 27 (24.5) | 13 (27.7) | 14 (22.2) | 23 (21) | 13 (27.7) | 10 (15.1) | 11 (9) | 9 (15) | 2 (3.8) |
| Question 3, n (%) | 55 (50) | 24 (51.1) | 31 (49.2) | 69 (63) | 35 (72.3) | 34 (54.7) | 28 (25) | 16 (31.9) | 12 (18.9) |
| Question 4, n (%) | 22 (20) | 11 (23.4) | 11 (17.5) | 29 (26) | 19 (38.3) | 10 (15.1) | 15 (14) | 13 (25.5) | 2 (3.8) |
| Question 5, n (%) | 76 (69.1) | 31 (66) | 45 (71.4) | 87 (79) | 37 (78.7) | 50 (79.2) | 25 (22.7) | 8 (17) | 17 (26.4) |
| Question 6, n (%) | 100 (90.9) | 40 (85.1) | 60 (95.2) | 105 (94) | 43 (91.5) | 62 (96.2) | 6 (6) | 5 (10.6) | 1 (1.9) |
| Question 7, n (%) | 78 (70.9) | 34 (72.3) | 44 (69.8) | 93 (85) | 41 (87.2) | 52 (83) | 21 (19) | 10 (21.3) | 11 (17) |
| Question 8, n (%) | 17 (15.5) | 7 (14.9) | 10 (15.9) | 18 (16) | 8 (17) | 10 (15.1) | 8 (7) | 3 (6.4) | 5 (7.5) |
| Question 9, n (%) | 20 (18.2) | 11 (23.4) | 9 (14.3) | 31 (28) | 17 (34) | 14 (22.6) | 18 (16) | 8 (17) | 10 (15.1) |
| Question 10, n (%) | 15 (13.6) | 7 (14.9) | 8 (12.7) | 24 (22) | 17 (34) | 17 (24) | 16 (15) | 10 (21.3) | 6 (9.4) |
| Question 11, n (%) | 68 (61.8) | 30 (63.8) | 38 (60.3) | 78 (71) | 34 (72.3) | 44 (69.8) | 25 (23) | 14 (29.8) | 11 (17) |
| Question 12, n (%) | 23 (20.9) | 14 (29.8) | 9 (14.3) | 36 (33) | 26 (53.2) | 10 (15.1) | 19 (17.3) | 14 (29.8) | 5 (7.9) |
| Question 13, n (%) | 73 (66.4) | 35 (74.5) | 38 (60.3) | 80 (73) | 43 (89.4) | 37 (58.5) | 20 (18) | 10 (21.3) | 10 (15.1) |
| Question 14, n (%) | 80 (72.7) | 34 (72.3) | 46 (73) | 88 (80) | 40 (85.1) | 48 (75.5) | 15 (14) | 8 (17) | 7 (11.3) |

N nutritional group, C control group
*No significant differences between C and N were observed in T0 values, while a significant difference was observed in T6 values (p<0.01) and in the T0–T6 change (p = 0.020)
* A significant difference between N and C was observed in question 12 (p = 0.048) at T0
* A significant difference between N and C was observed in question 4 (p = 0.008), in question 10 (p = 0.006), and in question 13 (p = 0.001) at T6
¶ A significant difference between N and C was observed in the T0–T6 change of question 1 (p = 0.033), question 4 (p = 0.002), and question 12 (p = 0.004), while for question 2 it was almost significant (p = 0.052)
Fig. 1 A PREDIMED score at T0 and T6 in all subjects, in the nutritional group, and in controls. B ASDAS-CRP at T0 and T6 in all subjects, in the nutritional group, and in controls. C ASDAS-CRP at T0 and T6 in all subjects, in subjects achieving a ≥ 20% PREDIMED improvement at T6 vs T0, and in those who did not. D Frequency of ≥20% PREDIMED improvement at T6 vs T0 in all subjects, in the nutritional group, and in controls. Frequency of ≥20% ASDAS-CRP improvement in all subjects, in the nutritional group, and in controls. E Frequency of ≥20% ASDAS-CRP improvement at T6 vs T0 in all subjects, in subjects achieving a ≥ 20% PREDIMED improvement at T6 vs T0, and in those who did not. In box plots (A–C), mean values are represented as X.
This improvement may be attributed to specific MD nutrients. During the study, patients receiving nutritional advice increased the consumption of olive oil and nuts which are rich in oleic acid and other n-3 polyunsaturated fats. There is evidence that n-3 polyunsaturated fatty acid supplementation—EPA and DHA, found in fish oil—associates with better disease activity scores in patients with rheumatoid arthritis [3, 11, 13]. These findings are further corroborated by studies showing that olive oil reduces inflammatory cytokine production and autoantibody development, increases T regulatory cell activation, and decreases Th17 response [7, 8, 30]. Furthermore, saturated fats and dietary fibers may also have an immunomodulatory effect on the gut microbiome in patients with autoimmune diseases [31].

Notably, although physical activity was not an outcome of the study, patients receiving nutritional advice more frequently reported increased physical activity as compared to controls. Physical activity reduces fatigue and improves sleep and innate immunity in SpA and rheumatoid arthritis patients [32, 33].

Psoriasis was negatively associated to ASDAS-CRP improvement, although this finding was not significant. Patients with psoriasis are known to have a heterogeneous disease, often representing a challenge for the rheumatologist [34]. Furthermore, these patients are often overweight, with an overlapping metabolic syndrome and a higher cardiovascular risk [14–16, 35–40]. Probably, axSpA patients with psoriasis will need studies with specific nutritional interventions.

Overall, a low cardiovascular risk was observed in all SpA patients in our cohort, irrespective of their diet, in line with previous findings of lower cardiovascular risk linked to Southern European diets [41, 42]. The lipid profile did not improve in our study nor did the blood pressure or SCORE and CUORE indices, which may be attributed to the short time of the study. Except from an improvement in blood pressure following a 6-week MD intervention in rheumatoid arthritis [26], no other study reports improvements of cardiovascular risk factors over a short time in rheumatic diseases and specifically in SpA [15].

The first limitation of this study is that the adherence to the MD was evaluated based on a questionnaire given to the patient and not with a regular meal control and hospital admission as in other studies in rheumatoid arthritis [27]. Questionnaires are prone to biased results from socially desirable answering [43]. Nonetheless, the adoption of a questionnaire allows to conduct a study in a large cohort of patients and is necessary to recall the dietary habits of the patients. Secondly, a 6-month study period may be regarded as a short time to evaluate diet.
and disease improvement following a dietary modification. An intrinsic problem of all studies considering nutritional intervention is to ensure an adequate and persistent adherence to the dietary modifications designed by the nutritionist: it has to be considered that a 6-month study challenges the patients’ compliance, making it difficult to maintain strict control over their eating habits for the course of study. This difficulty was one of the main reasons of drop-outs from the study, which was also affected by the isolation measures during the COVID emergency.

Conclusions
To date, this study is the first describing the effects of the MD in patients suffering from axSpA and reporting a successful modification of dietary habits and a trend toward an improvement of disease assessment. Higher BMI and a younger age patients affected by axSpA are less prone to modify their diet towards the Mediterranean diet following nutritional advice. A better adherence to the Mediterranean diet may improve disease activity in axSpA; nonetheless, patients with psoriasis may have a limited benefit from a dietary improvement. The results may be relevant for personalized treatment approaches for axSpA patients.

Abbreviations
ASAS: Assessment of Spondyloarthritis International Society; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score with C-reactive protein; axSpA: Axial spondyloarthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Ankylosing Spondylitis Enthesitis Score; BMI: Body mass index; C: Control group; cDMARD: Conventional disease-modifying antirheumatic drug; CI: Confidence interval; CRP: C-reactive protein; DMARD: Disease-modifying antirheumatic drug; ESR: Erythrocyte sedimentation rate; FBG: Fasting blood glucose; GGT: Gamma-glutamyltransferase; GOT: Glutamic oxaloacetic transaminase; GPT: Glutamic pyruvic transaminase; HAQ: Health Assessment Questionnaire; HB: Hemoglobin; HbA1c: Glycated hemoglobin; HDL-c: High-density lipoprotein cholesterol; I-CQR5: Italian version of the 5-item Compli- ance Questionnaire for Rheumatology; LDL-c: Low-density lipoprotein cholesterol; LEI: Leeds Enthesitis Index; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; MD: Mediterranean diet; N: Nutritional group; NSAID: Non-steroidal anti-inflammatory drug; OR: Odds ratio; PASI: Psoriasis Area Severity Index; PLT: Platelets; SCORE: Systematic coronary risk evaluation; SJC: Swollen joint count; SpA: Spondyloarthritis; TC: Total cholesterol; tDMARD: Targeted synthetic disease-modifying antirheumatic drug; TJC: Tender joint count; VAS: Visual analogue scale; VIF: Variance inflation factor; WBC: White blood count.
2. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Martín-Amada M, Cruz-Capanos M-G, et al. Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study. Rheumatology. 2020; 60(1):160–9. https://doi.org/10.1093/rheumatology/keaa210.

3. Petersson S, Philippou E, Rodomar C, Nikiporou E. The Mediterranean diet, fish oil supplements and rheumatoid arthritis outcomes: evidence from clinical trials. Autoimmune Rev. 2018;17:1105–14.

4. Vranou P, Gkoutzourelas A, Athanatou D, Zafiriou E, Grammatikopoulou MG, Ometto L, et al. Adherence in rheumatoid arthritis patients assessed with a validated Italian version of the 5-item Compliance Questionnaire for Rheumatology. Clin Exp Rheumatol. 2019;37(1):15–22.

5. Vedder D, Walanabenstein W, Heslinga M, de Vries R, Nicola P, Kvien TK, et al. Cardiovascular risk profile in patients with spondyloarthritis. Jt Bone Spine. 2020;87(4):222–8. https://doi.org/10.1016/j.jbspin.2019.12.019.

6. Venetasnopoulo AI, Voulgaris PV, Drosos AA. Fasting mimicking diets: a literature review of their impact on inflammatory arthritis. Med J Rheumatol. 2019;30(4):201–6. https://doi.org/10.1016/j.mjr.2019.04.201.

7. Khanna S, Jaiswal KS, Gupta B. Managing rheumatoid arthritis with dietary management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–8. https://doi.org/10.1136/ard.2009.103373.

8. Linos A, Kaklamani VG, Kaklamani E, Koumantaki Y, Giziaki E, Papazoglou S, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis. 2015;74(1):89–93. https://doi.org/10.1136/ard.2014.189984.

9. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Ometto L, et al. Mediterranean diet pyramid: a proposal for Italian nutritionists. Nutrients. 2019;11(12). https://doi.org/10.3390/nu11122955.

10. Petersson S, Philippou E, Rodomar C, Nikiporou E. The Mediterranean diet, fish oil supplements and rheumatoid arthritis outcomes: evidence from clinical trials. Autoimmune Rev. 2018;17:1105–14. https://doi.org/10.1016/j.autrev.2018.06.007.

11. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Ometto L, et al. Mediterranean diet, fish oil supplements and rheumatoid arthritis outcomes: evidence from clinical trials. Autoimmune Rev. 2018;17(11):105–14. https://doi.org/10.1016/j.autrev.2018.06.007.

12. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Ometto L, et al. Mediterranean diet pyramid: a proposal for Italian nutritionists. Nutrients. 2019;11(12). https://doi.org/10.3390/nu11122955.

13. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Ometto L, et al. Mediterranean diet pyramid: a proposal for Italian nutritionists. Nutrients. 2019;11(12). https://doi.org/10.3390/nu11122955.

14. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Ometto L, et al. Mediterranean diet pyramid: a proposal for Italian nutritionists. Nutrients. 2019;11(12). https://doi.org/10.3390/nu11122955.

15. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Ometto L, et al. Mediterranean diet pyramid: a proposal for Italian nutritionists. Nutrients. 2019;11(12). https://doi.org/10.3390/nu11122955.

16. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Ometto L, et al. Mediterranean diet pyramid: a proposal for Italian nutritionists. Nutrients. 2019;11(12). https://doi.org/10.3390/nu11122955.

17. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Ometto L, et al. Mediterranean diet pyramid: a proposal for Italian nutritionists. Nutrients. 2019;11(12). https://doi.org/10.3390/nu11122955.

18. Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio J-L, Ríos-Fernández R, Ometto L, et al. Mediterranean diet pyramid: a proposal for Italian nutritionists. Nutrients. 2019;11(12). https://doi.org/10.3390/nu11122955.
41. de Campos OAM, Nazário NO, de Magalhães Souza Fialho SC, Fialho GL, De Oliveira FJS, De Castro GRW, et al. Assessment of cardiovascular risk in patients with rheumatoid arthritis using the SCORE risk index. Rev Bras Reumatol. 2016;56(2):138–44. https://doi.org/10.1016/j.rbr.2015.07.007.

42. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol. 1986;124(6):903–15. https://doi.org/10.1093/oxfordjournals.aje.a114480.

43. Redelmeier DA, Dickinson VM. Determining whether a patient is feeling better: pitfalls from the science of human perception. J Gen Intern Med. 2011;26(8):900–6. https://doi.org/10.1007/s11606-011-1655-3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.